Is Surveillance Mammography Helpful for Older Survivors of Breast Cancer?

a physician talking with a patient

Cassie Shortsleeve

How to monitor women with a history of breast cancer as they age remains a gray area in medicine. Various guidelines on surveillance mammography in older patients exist — and suggest survivors continue regular mammograms, sometimes indefinitely — but the practice is not fully evidence-based.

“There are no data to support how we manage imaging in older breast cancer survivors,” said Rachel Freedman, MD, founder and medical director of the Program for Older Adults with Breast Cancer at Dana-Farber Cancer Institute in Boston. “Because of this, the default is annual mammography like we do in younger women.”

Yet regular mammograms do not appear to reduce the risk for a second primary breast cancer among older patients. A new study in JAMA Internal Medicine of 9888 women with an average age of 81 more than 5 years past a nonmetastatic breast cancer diagnosis found that advanced second primary breast cancers were rare — and no less common among women who kept up annual mammography than those who were screened less often.

The study adds to emerging data and consensus suggesting that surveillance decisions in older breast cancer survivors be individualized. Women-centered care in this population considers the burdens of continued surveillance, a woman’s life expectancy, and her preferences.
 
Generally, mammography is associated with about a 20% reduction in breast cancer mortality. Yet it takes at least 10 years for 1 in 1000 women to avoid a breast cancer death as a result of being screened, said Mara A. Schonberg, MD, MPH, program director at Harvard Medical School Fellowship in Primary Care Research in Boston. Older adults don’t always have that time and may have other, more threatening medical issues.
 
And while surveillance mammography aims to detect recurrence or second primary cancers early, to date, no clinical trial has specifically studied it in women aged 75 years or older — an age-based exclusion that’s “sadly true for many things in medicine,” said Louise Walter, MD, chief of the Division of Geriatrics at University of California, San Francisco.

The new JAMA Internal Medicine study only captured new breast cancers, not recurrences, yet the risk for recurrence is highest within the first 5 years after diagnosis — and women in the study were past that timeframe.

Women who have had breast cancer are also generally told they face a higher risk for a second cancer, but for older women, that risk is less clear.

“From what we know, the risk for second breast cancers in older adults likely mirrors the risk in the general population of older adults,” said Freedman. In those who have taken endocrine pills for their breast cancers, the risk is even lower as agents help lower the risk for in-breast cancers over time, she said.

While perhaps reassuring to some patients, a mammogram also does not diagnose cancer — and can lead to interventions with risks worth weighing.

“To me, a mammogram is not just a flu shot,” Walter said. In a 2001 study of 216 nursing-home-eligible women with an average age of 81 years, Walter found that 38 women had abnormal mammograms requiring further testing, four were diagnosed with breast cancer, and two died of other causes. In all, 42% of the women had pain or psychological distress as a result of screening.

In a population of older adults — particularly those with other medical illnesses such as dementia or heart failure — Walter said that focusing on mammograms can exacerbate other, more urgent issues. “The focus should have been on their current illnesses and how to help them live better.”

What Do Current Surveillance Guidelines Say — and Which Ones Do Providers Use?

There are various guidelines on surveillance mammography. The American Cancer Society recommends annual surveillance mammograms. In July, the American Society of Clinical Oncology (ASCO) updated its approach to a risk-based one, suggesting surveillance mammograms every 1-2 years for low-risk tumors after year 3. Risk stratification — as suggested by ASCO — could be “really challenging” for a busy primary care physician (PCP), said Larissa Nekhlyudov, MD, MPH, professor in the Department of Medicine at Harvard Medical School. Neither guideline includes life-expectancy language.

Most PCPs use the US Preventive Services Task Force guidelines, said Nekhlyudov, though they are indicated for the general population, not necessarily those with a history of cancer. These suggest insufficient evidence for screening after age 75 and shared decision-making.

“General breast cancer surveillance guidelines do not include carveouts for recommendations based on life expectancy, comorbidity, or age,” said Freedman. So in 2021, the International Society of Geriatric Oncology (ISGO) released a consensus statement with specific guidelines for older adults with a history of breast cancer. Recommendations include stopping screening at less than 5 years of life expectancy, considering stopping at 5-10 years, and continuing mammography when life expectancy is more than 10 years.

The National Comprehensive Cancer Network (NCCN) senior oncology guidelines also state that surveillance should be individualized, particularly for older adults, and incorporate comorbidities and life expectancies. Most PCPs may not even know about these guidelines, however, because providers need a login to access them, said Nekhlyudov.

Which Guidelines Are Useful for Older Women?

“The most important thing that’s going to determine whether someone’s going to get benefit or harm from pretty much any intervention is how sick they are and if they have other medical conditions,” said Walter. To determine this, many geriatric oncologists recommend using life expectancy when considering surveillance screening in older adults, as outlined in the ISGO recommendations.

Walter frames life expectancy as a tool for figuring out what matters most for any given patient. A woman with heart failure or dementia, for example, would benefit more from managing those conditions than from a test with a low chance of benefit and a higher risk for harm, since comorbidities can raise the risk for complications from any workup that follows. “It’s ‘how do we prioritize what is most likely going to help you?’” she said.

Most PCPs already know which patients have comorbidities that limit life expectancy. Tools such as ePrognosis and DecideTogether.info can also be utilized. For patients with less than 10 years’ life expectancy, communication is key. “I’m very much for shared decision-making in this controversial area,” said Schonberg.

Importantly, quality care and proper follow-up require close coordination between primary care and oncology, said Nekhlyudov.

And though less data-driven, patient preference matters. “If a woman wants to continue screening, she absolutely can and should,” said Freedman. “I just hope there is a discussion…rather than the knee-jerk reflex to just continue.”

Ultimately, particularly where data is lacking, the decision to continue surveillance mammograms is “not a simple algorithm,” Walter said. “It’s the art of medicine…and really thinking about the person in front of you.”

Freedman and Nekhlyudov reported having no relevant disclosures. Schonberg reported receiving royalties from UpToDate for having reviewed pages on prevention. Walter reported volunteering her time on two cancer screening guideline panels. She’s a Guideline Panel Member for the American Cancer Society Guidelines Development Group and vice-chair in the NCCN Older Adult Oncology Panel. The opinions she shared are her own and do not represent either of these guideline panels.